Back to top

Image: Bigstock

ImmunoGen, Inc.

Read MoreHide Full Article

ImmunoGen has made significant progress with regard to its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies, which not only validate its technology but also provide it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space is alos highly competitive, which is also a matter of concern for the company. The company’s shares have underperformed the industry in the past six months. Loss estimates remains stable ahead of Q4 earnings. Immunogen has a negative record of earnings surprises in the recent quarters.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ImmunoGen, Inc. (IMGN) - free report >>

Published in